QuidelOrtho Corporation

Equities

QDEL

US2197981051

Real-time Estimate Cboe BZX Other stock markets 17:44:39 17/02/2026 GMT			5-day change	1st Jan Change
23.24 ^USD	-1.44%		-19.79%	-17.96%

02-16	QuidelOrtho Corporation Enters Strategic Supply Agreement to Expand Global Immunoassay Portfolio	CI
02-13	Joseph M. Busky to Retire as Principal Financial Officer of Quidelortho Corporation, Effective as of June 30, 2026	CI

Transcript : QuidelOrtho Corporation, Q3 2025 Earnings Call, Nov 05, 2025

Published on 11/06/2025 at 10:41 am GMT

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Welcome to the QuidelOrtho Third Quarter 2025 Financial Results Conference Call and webcast. [Operator Instructions] Please note, this conference call

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about QuidelOrtho Corporation

02-16	QuidelOrtho Corporation Enters Strategic Supply Agreement to Expand Global Immunoassay Portfolio	CI
02-13	Joseph M. Busky to Retire as Principal Financial Officer of Quidelortho Corporation, Effective as of June 30, 2026	CI
02-12	UBS Adjusts QuidelOrtho Price Target to $30 From $35, Maintains Neutral Rating	MT
02-12	QuidelOrtho Corporation, Q4 2025 Earnings Call, Feb 11, 2026
02-11	QuidelOrtho Q4 Earnings Fall, Revenue Rises; Issues Guidance	MT
02-11	Earnings Flash (QDEL) QuidelOrtho Corporation Reports Q4 Revenue $723.6M, vs. FactSet Est of $700.7M	MT
02-11	Earnings Flash (QDEL) QuidelOrtho Corporation Posts Q4 Adjusted EPS $0.46 per Share, vs. FactSet Est of $0.42	MT
02-11	Joseph M. Busky to Retire as Chief Financial Officer of QuidelOrtho Corporation, Effective June 30, 2026	CI
02-11	QuidelOrtho Corporation Provides Earnings Guidance for the Fiscal Year 2026	CI
02-11	QuidelOrtho Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 28, 2025	CI
02-05	QuidelOrtho Corp Announces Departure of Director Matthew W. Strobeck	CI
01-21	UBS Adjusts QuidelOrtho Price Target to $35 From $31, Maintains Neutral Rating	MT
12-03	QuidelOrtho Corporation Presents at Citi Annual Global Healthcare Conference 2025, Dec-03-2025 01:00 PM
11-06	UBS Adjusts Price Target on QuidelOrtho to $31 From $26, Maintains Neutral Rating	MT
11-06	QuidelOrtho Corporation, Q3 2025 Earnings Call, Nov 05, 2025